Please login to the form below

Not currently logged in
Email:
Password:

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

Ipsen Dr Claude BertrandIpsen's executive vice president of research and development and chief scientific officer Dr Claude Bertrand has stepped down from his post.

He will be replaced by Dr Alexandre Lebeaut as interim head of research and development while the firm searches for a permanent successor.

Dr Bertrand joined the French pharmaceutical firm in 2009, having moved from AstraZeneca where he most recently served as global vice president for launched and established brands.

Prior to this, Dr Bertrand held director-level and senior research positions at Novartis, Pfizer and Roche.

David Meek, chief executive officer of Ipsen, said: “On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the R&D organization during the past seven years.

“We wish him well as he moves on to pursue a new opportunity.”

He added: “We are fortunate to have an experienced and successful R&D leader like Dr Lebeaut to step up and lead the R&D team.”

12th January 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...